Caliber Pain is Featured as a 2020 Top NYC Patient Rated Pain Management Practice by Find Local Doctors – PR Web

I am truly dedicated to helping my patients decrease pain, improve mobility and increase their overall quality of life. Being recognized by Find Local Doctors as a 2020 Top Patient Rated Doctor is such a huge honor, says Dr. Michael Fakhry

NEW YORK (PRWEB) October 09, 2020

Caliber Pain is New York Citys leading pain management practice, specializing in customized solutions for musculoskeletal pain and mobility issues. These board-certified physicians, led by Dr. Michael Fakhry, employ a multidisciplinary approach combined with the latest non-surgical, evidence-based interventional procedures at their state-of-the-art AAAHC accredited facility in Manhattan. Caliber Pain has gained the attention of Find Local Doctors for the consistent, exceptional reviews they have received from patients. An easy-to-navigate online directory, Find Local Doctors helps consumers connect with local physicians who are highly-qualified and reputable.

Caliber Pain offers interventional treatments and regenerative medicine for a wide variety of injuries and pain issues and are committed to using a multidisciplinary approach to treating patients. They focus on each individual patients needs and goals, from restoring simple mobility issues to the relief of chronic and complex pain conditions. The medical team creates well-rounded treatment plans that include multiple disciplines and procedures, combining injection therapy such as PRP and STEM cell regenerative treatments), ketamine infusions, physical therapy, nerve blocks, spinal cord stimulation and other options to ensure patients have short and long-term pain management. The experienced specialists at Caliber Pain utilize the latest medical technology and work closely with patients, from the initial diagnosis to mapping out an effective treatment program. Many reviews of this practice have mentioned the highly knowledgeable, compassionate staff and the attentive care they received.

I am truly dedicated to helping my patients decrease pain, improve mobility and increase their overall quality of life. Being recognized by Find Local Doctors as a 2020 Top Patient Rated Doctor is such a huge honor, says Dr. Michael Fakhry

More about Dr. Michael Fakhry:

Dr. Michael Fakhry is an interventional pain management specialist who is double board-certified in anesthesiology and pain medicine. Dr. Fakhry graduated from the accelerated BA/MD joint program with Rutgers University and Robert Wood Johnson Medical School. He then completed his residency in anesthesiology at NYU Medical Center in Manhattan. Following his residency, he completed his fellowship in interventional pain management at NYU where he trained at both academic and public hospitals. Dr. Fakhry is a leader in his field and has published research in numerous medical journals and presented at national and international conferences. Caliber Pain is located at 737 Park Avenue 1C in New York, NY, and can provide a same day diagnosis and interventional pain treatments. Call (212) 203-5987, or visit http://www.caliberpain.com today to schedule your appointment for effective pain management.

Share article on social media or email:

Read the rest here:
Caliber Pain is Featured as a 2020 Top NYC Patient Rated Pain Management Practice by Find Local Doctors - PR Web

Report of the president: Appointments and promotions | Stanford News – Stanford University News

APPOINTMENTS WITHOUT LIMIT OF TIME:

DeSimone, Joseph, Professor of Radiology and of Chemical Engineering, effective September 1, 2020

Hernandez-Boussard, Tina, Associate Professor of Medicine, and by courtesy, of Surgery, effective November 1, 2020

Rose, Sherri, Associate Professor of Medicine, effective August 1, 2020.

Setsompop, Kawin, Associate Professor of Radiology, effective November 1, 2020

PROMOTIONS WITHOUT LIMIT OF TIME:

Bauer, Andrew, Associate Professor of Anthropology, effective September 1, 2020

Collins, Steven, Associate Professor of Mechanical Engineering, effective November 1, 2020

Dixon, Scott, Associate Professor of Biology, effective January 1, 2021

Feng, Liang, Associate Professor of Molecular and Cellular Physiology, effective October 1, 2020

Goldbogen, Jeremy, Associate Professor of Biology, effective January 1, 2021

Gweon, Hyowon, Associate Professor of Psychology, effective September 1, 2020

Huh, June, Professor of Mathematics, effective September 1, 2020

Pasa, Sergiu, Associate Professor of Psychiatry and Behavioral Sciences, effective August 1, 2020

Rivas-Davila, Juan, Associate Professor of Electrical Engineering, effective September 1, 2020

Seetah, Krish, Associate Professor of Anthropology, effective August 1, 2020

Simard, Julia, Associate Professor of Epidemiology and Population Health, and by courtesy, of Medicine, effective January 1, 2021

Stanford, Douglas, Associate Professor of Physics, effective September 1, 2020

Yan Xia, Associate Professor of Chemistry, effective September 1, 2020

PROMOTION FOR A CONTINUING TERM:

Srivastava, Sakti, Professor (Teaching) of Surgery, effective October 1, 2020

OTHER APPOINTMENTS:

Achour, Sara, Assistant Professor (subject to Ph.D.) of Computer Science, for the period September 1, 2020 through August 31, 2024

Allende Santa Cruz, Claudia, Assistant Professor of Economics in the Graduate School of Business, for the period July 1, 2021 through June 30, 2025

Banik, Steven, Assistant Professor of Chemistry, for the period September 1, 2021 through August 31, 2025

Bouland, Adam, Assistant Professor of Computer Science, for the period September 1, 2020 through August 31, 2024

Chaudhari, Akshay, Assistant Professor (Research) of Radiology, for the period October 1, 2020 through September 30, 2024, coterminous with continued salary and research funding from sponsored projects

Clark, Susan, Assistant Professor of Physics, for the period September 1, 2021 through August 31, 2025

Fletcher, Brian, Associate Professor (Teaching) of Law, for the period September 1, 2020 through August 31, 2023

Geldsetzer, Pascal, Assistant Professor of Medicine, for the period November 1, 2020 through October 31, 2024

Kasowski, Maya, Assistant Professor of Medicine and of Pathology, and by courtesy, of Genetics, for the period July 1, 2020 through June 20, 2024

Kozleski, Elizabeth, Professor (Research) of Education, for the period August 31, 2020 through August 30, 2025, coterminous with continued salary and research funding from sponsored projects

Liu, Fang, Assistant Professor of Chemistry, for the period September 1, 2020 through August 31, 2024

Mason, Daniel, Assistant Professor of Psychiatry and Behavioral Sciences, for the period October 1, 2020 through September 30, 2024

Sharaf, Naima, Assistant Professor of Biology, for the period September 1, 2021 through August 31, 2025

Trivedi, Mudit, Assistant Professor (subject to Ph.D.) of Anthropology, for the period July 1, 2021 through June 30, 2025

OTHER PROMOTIONS:

Blanchet, Jose, Professor of Management Science and Engineering, effective September 1, 2020

Gipper, Brandon, Associate Professor of Accounting in the Graduate School of Business, for the period July 1, 2020 through June 30, 2023

Hbert, Benjamin, Associate Professor of Finance in the Graduate School of Business, for the period August 1, 2020 through July 31, 2023

Heilshorn, Sarah, Professor of Materials Science and Engineering, and by courtesy, of Chemical Engineering and of Bioengineering, effective August 1, 2020

Spakowitz, Andrew, Professor of Chemical Engineering and of Materials Science and Engineering, effective September 1, 2020

Yang, Peter, Professor of Orthopaedic Surgery, effective October 1, 2020

OTHER REAPPOINTMENTS:

Auclert, Adrien, Assistant Professor of Economics, for the period July 1, 2023 through June 30, 2024

Bacchetta, Rosa, Associate Professor (Research) of Pediatrics, for the period August 1, 2020 through April 30, 2025, coterminous with continued salary and research funding from sponsored projects

Baiocchi, Michael, Assistant Professor of Epidemiology and Population Health and, by courtesy, of Statistics and of Medicine, for the period September 1, 2021 through August, 2022

Battiato, Ilenia, Assistant Professor of Earth System Science, for the period September 1, 2020 through August 31, 2023

Bernert, Rebecca, Assistant Professor of Psychiatry and Behavioral Sciences, for the period October 1, 2021 through September 30, 2022

Bocolo, Luigi, Assistant Professor of Economics, for the period August 1, 2022 through July 31, 2023

Boettiger, Alistair, Assistant Professor of Developmental Biology, for the period September 1, 2020 through August 31, 2023

Brandman, Onn, Assistant Professor of Biochemistry, for the period September 1, 2020 through November 30, 2020

Chan, David, Assistant Professor of Medicine, for the period November 1, 2022 through October 31, 2023

Chaudhuri, Ovijit, Assistant Professor of Mechanical Engineering, for the period August 1, 2020 through September 30, 2020

Clement, Julien, Assistant Professor of Organizational Behavior in the Graduate School of Business, for the period July 17, 2022 through July 16, 2023

Cuesta Rodriguez, Jos, Assistant Professor of Economics, for the period July 1, 2024 through June 30, 2026

Dubra, Alfredo, Associate Professor of Ophthalmology, for the period September 1, 2020 through August 31, 2021

Duncan, Laramie, Assistant Professor of Psychiatry and Behavioral Sciences, for the period September 1, 2022 through August 31, 2023

Dunn, Laura, Professor of Psychiatry and Behavioral Sciences, for the period September 1, 2020 through November 30, 2020

Dylan, Dodd, Assistant Professor of Pathology and of Microbiology and Immunology, for the period August 16, 2022 through August 15, 2023

Ellsworth, William, Professor (Research) of Geophysics, for the period October 4, 2020 through October 3, 2025, coterminous with continued salary and research funding from sponsored projects

Feldman, Brian, Assistant Professor of Physics, for the period September 1, 2021 through December 31, 2021

Fetter, Dan, Assistant Professor of Economics, for the period July 1, 2024 through June 30, 2025

Frock, Richard, Assistant Professor of Radiation Oncology, for the period January 1, 2022 through December 31, 2022

Fung, Lawrence, Assistant Professor of Psychiatry and Behavioral Sciences, for the period July 1, 2023 through June 30, 2024

Gao, Xiaojing, Assistant Professor of Chemical Engineering, for the period April 1, 2024 through March 31, 2025

Garcia, Antero, Assistant Professor of Education, for the period January 1, 2021 through December 31, 2023

Gorle, Catherine, Assistant Professor of Civil and Environmental Engineering, for the period July 1, 2020 through June 30, 2024

Grillet, Nicolas, Assistant Professor of Otolaryngology Head and Neck Surgery, for the period April 1, 2023 through March 31, 2024

Gross, Eric, Assistant Professor of Anesthesiology, Perioperative and Pain Medicine, for the period September 1, 2021 through August 31, 2022

Gu, Xun, Assistant Professor of Mechanical Engineering and, by courtesy, of Materials Science and Engineering, for the period June 1, 2022 through May 31, 2023

Heaney, Catherine, Associate Professor (Teaching) of Psychology and of Medicine, for the period July 1, 2020 through June 30, 2025

Hebert, Benjamin, Associate Professor of Finance in the Graduate School of Business, for the period August 1, 2023 through July 31, 2024

Hoffman, Mark, Assistant Professor of Sociology, for the period October 16, 2023 through October 15, 2024

Honigsberg, Colleen, Associate Professor of Law, for the period June 1, 2023 through May 31, 2025

Hu, Yang, Assistant Professor of Ophthalmology, for the period December 1, 2020 through November 30, 2021

Huang, Possu, Assistant Professor of Bioengineering, for the period October 1, 2020 through August 31, 2022

Huang, Ting Ting, Associate Professor (Research) of Neurology and Neurological Sciences, for the period November 1, 2020 through October 31, 2021, coterminous with continued salary and research funding from sponsored projects

Iyer, Usha, Assistant Professor of Art and Art History, for the period June 1, 2023 through May 31, 2024

Jagannathan, Prassana, Assistant Professor of Medicine and of Microbiology and Immunology, for the period January 1, 2021 through December 31, 2023

Jaiswal, Siddhartha, Assistant Professor of Pathology, for the period November 1, 2021 through October 31, 2022

Kaltschmidt, Julia, Associate Professor of Neurosurgery, for the period April 1, 2021 through March 31, 2022

Kantor, Roanne, Assistant Professor of English, for the period July 1, 2022 through June 30, 2023

Kasowski, Maya, Assistant Professor of Medicine, and by courtesy, of Genetics, for the period July 1, 2024 through June 30, 2025

Keca, Srdan, Assistant Professor of Art and Art History, for the period September 1, 2023 through August 31, 2024

Konermann, Silvana, Assistant Professor of Biochemistry, for the period October 1, 2023 through September 30, 2024

Konings, Alexandra, Assistant Professor of Earth System Science, for the period September 1, 2020 through August 31, 2023

Kronengold, Charles, Assistant Professor of Music, for the period January 1, 2021 through June 30, 2022

Kundaje, Anshul, Assistant Professor of Genetics and of Computer Science, for the period December 1, 2020 through November 30. 2022

Kwon, Marci, Assistant Professor of Art and Art History, for the period August 1, 2023 through July 31, 2024

Larson, Bradley, Assistant Professor of Economics, for the period August 1, 2023 through July 30, 2024

Linderman, Scott, Assistant Professor of Statistics, for the period June 1, 2023 through May 31, 2025

Long, Jonathan, Assistant Professor of Pathology, for the period January 1, 2023 through December 1, 2023

Mai, Danielle, Assistant Professor of Chemical Engineering, for the period January 1, 2024 through December 31, 2024

Mannix, Andrew, Assistant Professor of Materials Science and Engineering, for the period August 1, 2024 through July 31, 2025

Martinez-Martin, Nicole, Assistant Professor (Research) of Pediatrics, for the period December 1, 2023 through November 30, 2024, coterminous with continued salary and research funding from sponsored projects

Morten, Melanie, Assistant Professor of Economics, for the period July 1, 2021 through June 30, 2022

Mross, Michaela, Assistant Professor of Religious Studies, for the period September 1, 2023 through August 31, 2024

Newman, Aaron, Assistant Professor of Biomedical Data Science, for the period August 1, 2021 through July 31, 2022

Palacios, Julia, Assistant Professor of Statistics and of Biomedical Data Science, for the period September 1, 2021 through August 31, 2024

Read the original here:
Report of the president: Appointments and promotions | Stanford News - Stanford University News

UTSW Scientist: ‘We Need More Women Thinking Creatively in the Lab and Pushing Science Forward’ – dallasinnovates.com

[Image: Oleksandr Bushko/istockphoto]

Its rare to have a woman winning a Nobel Prize, much less two women on the same day and three in the same year, a UTSW spokesperson told us as the news rolled out about this years winners.

American biochemist Jennifer Doudna and French Emmanuelle Charpentier became the first women to jointly win the Nobel Prize in Chemistry on Tuesday. They are the sixth and seventh women to ever win that prize. American astrophysicist Andrea Ghez, along with two others, won the Nobel Prize in physics for their discoveries about black holes on Monday.

UTSW scientist Eric Olson spent the day on a Zoom call with Nobel Prize winner Doudna earlier this week. Olson, who uses CRISPR technology in studies that might one day repair many of the mutations that cause Duchenne muscular dystrophy, called the prize great news.

Doudna and her colleague Charpentier have revolutionized science, biotechnology, and medicine with the development of CRISPR as a gene-editing tool, says Olson, who is the director of UTSWs Hamon Center for Regenerative Science and Medicine and professor and chair of molecular biology.

UT Southwesterns Dr. Eric Olson works with longtime collaborator Dr. Jay Schneider, an adjunct associate professor of internal medicine-cardiology. [Photo: UTSW]

CRISPR forms the basis of a primitive bacterial immune system, which they cleverly adapted to modify the genomes of any organism in a simple and efficient manner, Olson explains.

There are many ways CRISPR gene editing can benefit humanity, he says. The technology is already enabling the elimination of genetic mutations that cause devastating human diseases, Olson says. The breakthrough discovery of Doudna and Charpentier exemplifies the power of basic science to change the world in powerful ways.

The UTSW professor also co-founded Exonics Therapeutics, a Massachusetts-based biotech company that uses CRISPR technology licensed from UT Southwestern Medical Center in Dallas, that acquired in 2019 by Vertex Pharmaceuticals in a deal roughly valued at $1 billion. The scientist launched Exonics in February 2017 to advance and commercialize his research. The company develops treatments for Duchenne muscular dystrophy and other genetic neuromuscular diseases.

Olson works with Professor Rhonda Bassel-Duby, Ph.D., a highly cited researcher who helps run the Olson laboratory.

UT Southwestern Professor Rhonda Bassel-Duby [Photo: UTSW]

Bassel-Duby says its wonderful that the Nobel Prize in Chemistry was awarded to two woman who richly deserve the prize. She hopes the award encourages young women to consider a career in science: Doing scientific research is one of the most enriching and fulfilling professions. We need more women thinking creatively in the lab and pushing science forward, Bassel-Duby says.

Olson and Bassel-Duby work alongside longtime collaborator Jay Schneider, an M.D. and Ph.D. who is an adjunct associate professor of internal medicine-cardiology.

Olson holds the Annie and Willie Nelson Professorship in Stem Cell Research, the Pogue Distinguished Chair in Research on Cardiac Birth Defects, and The Robert A. Welch Distinguished Chair in Science.

Sign up to keep your eye on whats new and next in Dallas-Fort Worth, every day.

Take a look back on the stories that grabbed our readers' attention last month.

FusionFlight, which received a $50,000 seed investment in 2016, has built and tested "the world's smallest and most powerful jet-powered drone with vertical take-off and landing capabilities."

There are plenty of things to do withyourphysically distanced time. Here are a few from our curated selection.

Taysha Gene Therapies, which has been operating in stealth with UT Southwestern, is off to a fast start with a pipeline of 15 gene therapy programs. Together with UTSW, the combined platform could be"an engine for new cures."

Taysha Gene Therapies, which was been operating in stealth with UT Southwestern until this April, plans to use the financing to advance its initial cohort of lead programs into its clinic. By the end of 2021, Taysha expects to file four Investigational New Drug applications.

Read more from the original source:
UTSW Scientist: 'We Need More Women Thinking Creatively in the Lab and Pushing Science Forward' - dallasinnovates.com

Here’s what is known about Trump’s COVID-19 treatment – Science Magazine

President Donald Trump has maintained a steady schedule of campaign rallies, which may have exposed him to SARS-CoV-2.

By Jon CohenOct. 2, 2020 , 9:25 PM

Sciences COVID-19 reporting is supported by the Pulitzer Center and the Heising-Simons Foundation.

This afternoon, the White House announced that President Donald Trump received an experimental antibody treatment after a test revealed he'sinfected with SARS-CoV-2. He reportedly has mild COVID-19 symptoms, including fever and congestion, and he was transferred to Walter Reed National Military Medical Center. Later, the president's medical team confirmed he had started a course of remdesivir, an antiviral drug shown to modestly help hospitalized COVID-19 patients.

What is the antibody cocktail Trump received?

Its a combination of two antibodies directed against a key protein of the virus that causes COVID-19, SARS-CoV-2. They bind to a region on the main surface spike protein that helps the virus attach to a receptor on human cells called angiotensin-converting enzyme 2 (ACE2). The targeted region is dubbed the receptor binding domain. One antibody comes from a human who had recovered from a SARS-CoV-2 infection; a B cell that makes the antibody was harvested from the persons blood and the genes for the immune protein isolated and copied. The other antibody is from a mouse, which was engineered to have a human immune system, that had the spike protein injected into it.

Are there any data showing that the cocktail works and is safe?

Experiments in both golden hamsters and rhesus macaque monkeys that intentionally were infected with SARS-CoV-2 showed that the cocktail could reduce viral levels and disease pathology.

Regeneron, the maker of the cocktail, earlier this week presented preliminary data from its ongoing clinical trial in people who tested positive for SARS-CoV-2 but were asymptomatic or, in the most extreme cases, had moderate diseasea group that would appear to mirror Trumps current condition. No serious safety concerns surfaced, and the treatment reduced viral load and shortened symptomatic disease in patients who did not have SARS-CoV-2 antibodies at the trials start. Its unclear whether the treatment can prevent severe disease, but there were hints that it might: Participants who received a placebo had more medical visits.

A separate trial is assessing the impact of the treatment on hospitalized COVID-19 patients, but Regeneron has yet to report any results from that study.

Do the preliminary clinical trial data match the presidents treatment scheme?

Not exactly. Trump received an 8-gram infusion of the treatment. Regenerons data showed that a 2.4-gram infusion worked as well as the higher dose at reducing SARS-CoV-2 levels in people. This was widely seen as good news because monoclonals are difficult and expensive to produce, and a lower dose means that more people ultimately can receive it.

Why did the president receive the higher dose of the antibodies?

Likely out of an abundance of caution by the presidents medical team, says George Yancopoulos, the co-founder and chief scientific officer of Regeneron. Yancopoulos does not directly know why Trump'sphysicians chose to use 8 grams, but says the companys data indicate theres very, very limited risk that the antibodies will cause harm at either dose. The higher dose might last longer, he said, and at some time points in the companys study, Regeneron did see trends suggesting that the higher dose more powerfully beats back the virusthe company used the amount of viral genetic material found with nose swabs as a proxy for SARS-CoV-2 levels in the entire body.

If I had to treat one patient, Id give the high dose, Yancopoulos says. From a societal point of view and the need to treat as many people as possible, Id give the lower dose.

Did Trump match the patients in the study who benefited from the treatment?

The Regeneron study found that the treatment only worked in people who did not have SARS-CoV-2 antibodies at the start of the study. It also worked best in people who had higher levels of the virus. Whether the president had those antibodies and a high viral load has not been made public. I couldnt speculate because it has to do with an individual patient, Yancopoulos says.

The memorandum from the presidents physician said Trump was receivingRegenerons polyclonal antibody cocktail. Are these antibodies polyclonal?

No. The treatment consisted of two monoclonal antibodiesmeaning each was produced by making identical copies, or clones, of an antibody gene in a single B cell. Polyclonal antibody cocktails refer to antibodies made by mixtures of B cells.

What was the regulatory mechanism that allowed the president to receive the experimental Regeneron antibodies?

The antibodies are typically only available to people who participate in clinical trials. Trump theoretically could have enrolled in the ongoing treatment study that reported preliminary data this week, but that trial randomly assigns half the participants to receive the antibodies; the other half serves as a control group and receives infusions of an inactive placebo. A U.S. Food and Drug Administration (FDA) regulation called expanded accesstechnically known as 21 CFR 312.310allows physicians to request compassionate use of experimental treatments through an investigational new drug pathway used for individual patients or for emergencies. These are designed to be used in these rare and special circumstances, Yancopoulos says. This is not the first time weve done compassionate use for these monoclonal antibodies. This is not a mechanism for widespread distribution.

Could Regenerons monoclonal antibody treatment become more widely available through the FDAs emergency use authorization (EUA) pathway?

Yes. Both Regeneron and Eli Lilly, which similarly reported encouraging preliminary clinical trial data last month from a single SARS-CoV-2 monoclonal antibody, are discussing the possibility of an EUA with FDA. Lilly reported signs that its antibody reduced the need for hospitalization, but as with Regeneron, too few participants have so far become seriously ill to reach a convincing conclusion to this critical question.

What's the evidence for using remdesivir in COVID-19 patients?

Remdesivir is an antiviral drug developed by Gilead Sciences, originally to treat the hepatitis C virus. It did not perform well against that pathogen but has been tried against Ebola and other viruses, after showing some activity in cells and animal models. The drug inhibits a viral enzyme used for replication of the pathogen. Earlier this year, it demonstrated a modest clinical benefit in a trial with hospitalized COVID-19 patients, leading FDA to grant Gilead an emergency use authorization for the drug. That EUA has since been expanded for use in patients with mild disease although its benefit in them is not clear. The drug has become widely used for COVID-19 patients despite continuing skepticism that it has a major clinical benefit. Since it and the monoclonal antibodies target different parts of the virus, administering them together may have a synergistic effect. One COVID-19 clinical trial is testing remdesivir and Lilly's antibody, for example.

Is the president receiving any other COVID-19 treatments?

The statement released today by the presidents physician said that in addition to the antibodies, Trump has been taking zinc, vitamin D, famotidine, melatonin and a daily aspirin. That wording leaves unclear whether he was taking those substances before his diagnosed infection. Notably, the statement does not indicate whetherTrump was or is taking hydroxychloroquine, the antimalarial he controversially pushed as a COVID-19 treatment.

Famotidine has been suggested to be a treatment for COVID-19, but its also a popular heartburn remedy, sold widely under the name Pepcid. A clinical trial testing it in hospitalized COVID-19 patients in New York was not able to recruit enough patients to properly evaluate its impact. The Feinstein Institutes for Medical Research, which initiated that trial, released a statement today citing evidence it was helpful for COVID-19 but also saying, We have yet to prove [famotidines] efficacy. The institute says its eagerly awaiting FDA approval of a trial that will evaluate whether famotidine can help people who are not hospitalized.

*Updated, 3 October, 6 a.m.: Information about Trumps's use of remdesivir was added to the story.

The rest is here:
Here's what is known about Trump's COVID-19 treatment - Science Magazine

Election Guide: Here’s What You Need to Know About Proposition 14 – NBC Bay Area

Proposition 14 on the November ballot asks voters to approve $5.5 billion to continue funding stem cell research in California.

Supporters said the research has already lead to important medical breakthroughs, including for COVID-19 victims. Opponents said the proposition is more "shameless overpromising" with money that could be better spent elsewhere.

California voters have been though this before.

In 2004, state voters approved Proposition 71, which meant $3 billion for stem cell research and to establish the California Institute of Regenerative Medicine, or CIRM. The group's chairman and Proposition 14's financial backer, Robert Klein, said that money has lead to significant medical breakthroughs.

But now, CIRM is almost out of money, and Proposition 14 asks voters for $5.5 more for stem cell research.

"If 70 different patient advocacy organizations, from the Michael J. Fox Foundation to the American Diabetes Foundation and the American Association of Cancer Researchers all endorse us -- could they all be wrong?" Klein asked.

Longtime AIDS activist Jeff Sheehy is on the CIRM board and said residents are still paying $325 million a year for Proposition 71.

"We're going to add another $300 million on top of that -- that's two-thirds of $1 billion for stem cell research," Sheehy said. "We don't have a single FDA approved product yet."

Sheehy said taxpayer funding of stem cell research was needed back in 2004 when California was on its own, but now the feds and private industry are spending billions on it every year.

"So we're just duplicating," Sheehy said.

Marcy Darnovsky, executive director of the Center for Genetics and Society, opposes Proposition 14 because of CIRM's quote "Shameless overpromising and hype set the stage for hundreds of underregulated commercial stem cell clinics now offering unapproved treatments that have caused tumors and blindness."

"All those people who survive COVID-19, they are finding up to 50% have heart damage and other organ damage," Darnovsky said. "How are you going to regenerate those tissues? Regenerative medicine is still cell therapy."

Dr. Michael Matthay professor of critical care medicine at UCSF, said CIRM has provided grant money to help research COVID-19 treatments.

"We are using cell based therapy to reduce injury to longs from COVID-19 and to accelerate the recovery process," Matthay said.

It should be pointed out everyone interviewed for this story are in favor of stem cell research -- Darnovsky and Sheehy believe that the billions of dollars being asked of taxpayers could be better spent on education, healthcare, housing and jobs.

See the article here:
Election Guide: Here's What You Need to Know About Proposition 14 - NBC Bay Area

ASX up 2.3%, banks and energy outperform – The Sydney Morning Herald

ASX-listed biopharma Opthea Limited has named Ovid Therapeutics founder and chief executive Dr Jeremy Levin as its new chairman.

Dr Levin, who concurrently chairs the Biotechnology Innovation Organisation, the largest trade organisation in the world that represents the biotechnology industry, will replace outgoing chair Geoffrey Kempler at the firms annual general meeting on October 13.

Opthea said Dr Levins track record and experience in the biotechnology and pharmaceutical industry will be instrumental as the company advances its Phase 3-ready product candidate, OPT-302, for the treatment of wet age-related macular degeneration and diabetic macular edema conditions.

Prior to founding Ovid, the South African-born Dr Levin was president and chief executive of Teva Pharmaceutical Industries Ltd and before Teva, was a member of the executive committee of Bristol-Myers Squibb Company.

He has served on the board of directors of various public and private biopharmaceutical companies, including Biocon Ltd and is currently on the board of directors of Lundbeck.

Shares in Opthea were 0.7 per cent lower at $2.81 at 11am against a 2 per cent rise for the ASX200. The companys share price has dipped 5.7 per cent in 2020. The wider index has fallen 11.5 per cent.

Continued here:
ASX up 2.3%, banks and energy outperform - The Sydney Morning Herald

Autologous Stem Cell and Non-Stem Cell Based Therapies MARKET 2020 |INDUSTRY ANALYSIS, SIZE, SHARE, TRENDS, MARKET DEMAND, GROWTH, OPPORTUNITIES AND…

This report focuses on the Global Autologous Stem Cell and Non-Stem Cell Based Therapies Market trends, future forecasts, growth opportunities, key end-user industries, and market players. The objectives of the study are to present the key developments of the market across the globe.

The latest research report on Autologous Stem Cell and Non-Stem Cell Based Therapies market encompasses a detailed compilation of this industry, and a creditable overview of its segmentation. In short, the study incorporates a generic overview of the Autologous Stem Cell and Non-Stem Cell Based Therapies market based on its current status and market size, in terms of volume and returns. The study also comprises a summary of important data considering the geographical terrain of the industry as well as the industry players that seem to have achieved a powerful status across the Autologous Stem Cell and Non-Stem Cell Based Therapies market.

Get Sample of this Premium Report @ https://brandessenceresearch.biz/Request/Sample?ResearchPostId=148458&RequestType=Sample

Autologous Stem Cell and Non-Stem Cell Based Therapies Market Segmentation

By Type Autologous Stem Cell, Non-Stem Cell,

By Application Medical Centers and Universities, Clinical Laboratories,

The report has been curated after observing and studying various factors that determine regional growth such as economic, environmental, social, technological, and political status of the particular region. Analysts have studied the data of revenue, production, and manufacturers of each region. This section analyses region-wise revenue and volume for the forecast period of 2015 to 2026. These analyses will help the reader to understand the potential worth of investment in a particular region.

Global Autologous Stem Cell and Non-Stem Cell Based Therapies Market: Competitive Landscape This section of the report identifies various key manufacturers of the market. It helps the reader understand the strategies and collaborations that players are focusing on combat competition in the market. The comprehensive report provides a significant microscopic look at the market. The reader can identify the footprints of the manufacturers by knowing about the global revenue of manufacturers, the global price of manufacturers, and production by manufacturers during the forecast period of 2015 to 2020.

The major players in the market ANTRIA (CRO) (U.S.), BIOHEART (U.S.), BRAINSTORM CELL THERAPEUTICS (U.S.), CYTORI (U.S.), DENDREON CORPORATION (U.S.), FIBROCELL (U.S.), GENESIS BIOPHARMA (U.S.), GEORGIA HEALTH SCIENCES UNIVERSITY (U.S.), NEOSTEM (U.S.), OPEXA THERAPEUTICS (U.S.), ORGENESIS (U.S.), REGENEXX (U.S.), REGENEUS (AUSTRALIA), TENGION (U.S.), TIGENIX (BELGIUM), VIRXSYS (U.S.)

Global Autologous Stem Cell and Non-Stem Cell Based Therapies MarketThis research report providesCOVID-19 Outbreakstudy accumulated to offer Latest insights about acute features of the Autologous Stem Cell and Non-Stem Cell Based Therapies Market. The report contains different market predictions related to marketsize, revenue, production, CAGR, Consumption, gross margin, price, and other substantial factors. While emphasizing the key driving and restraining forces for this market, the report also offers a complete study of the future trends and developments of the market. It also examines the role of the leading market players involved in the industry including their corporate overview, financial summary andSWOT analysis.It presents the360-degreeoverview of the competitive landscape of the industries. Autologous Stem Cell and Non-Stem Cell Based Therapies Market is showing steadygrowthandCAGRis expected to improve during the forecast period.

The main sources are industry experts from the global Autologous Stem Cell and Non-Stem Cell Based Therapies industry, including management organizations, processing organizations, and analytical services providers that address the value chain of industry organizations. We interviewed all major sources to collect and certify qualitative and quantitative information and to determine future prospects. The qualities of this study in the industry experts industry, such as CEO, vice president, marketing director, technology and innovation director, founder and key executives of key core companies and institutions in major biomass waste containers around the world in the extensive primary research conducted for this study We interviewed to acquire and verify both sides and quantitative aspects.

Global Autologous Stem Cell and Non-Stem Cell Based Therapies Market: Regional Analysis The report offers in-depth assessment of the growth and other aspects of the Autologous Stem Cell and Non-Stem Cell Based Therapies market in important regions, including the U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, Taiwan, Southeast Asia, Mexico, and Brazil, etc. Key regions covered in the report are North America, Europe, Asia-Pacific and Latin America.

Do You Have Any Query Or Specific Requirement @https://brandessenceresearch.biz/Request/Sample?ResearchPostId=148458&RequestType=Methodology

Complete Analysis of the Autologous Stem Cell and Non-Stem Cell Based Therapies Market:

Comprehensive assessable analysis of the industry is provided for the period of 2020-2025 to help investors to capitalize on the essential market opportunities.

The key findings and recommendations highlight vital progressive industry trends in the global Autologous Stem Cell and Non-Stem Cell Based Therapies market, thereby allowing players to improve effective long term policies

A complete analysis of the factors that drive market evolution is provided in the report.

To analyze opportunities in the market for stakeholders by categorizing the high-growth segments of the market

The numerous opportunities in the Autologous Stem Cell and Non-Stem Cell Based Therapies market are also given.

Report Answers Following Questions:

What are the factors driving the growth of the market?

What factors are inhibiting market growth?

What are the future opportunities in the market?

Which are the most dynamic companies and what are their recent developments within the Autologous Stem Cell and Non-Stem Cell Based Therapies Market?

What key developments can be expected in the coming years?

What are the key trends observed in the market?

TABLE OF CONTENT

1 Report Overview

2 Global Growth Trends

3 Market Share by Key Players

4 Breakdown Data by Type and Application

5 United States

6 Europe

7 China

8 Japan

9 Southeast Asia

10 India

11 Central & South America

12 International Players Profiles

13 Market Forecast 2020-2025

14 Analysts Viewpoints/Conclusions

15 Appendix

Read Full Report: https://brandessenceresearch.biz/Lifesciences-and-Healthcare/Global-and-Regional-Autologous-Stem-Cell-and-Non-Stem-Cell-Based-Therapies-Industry-Production-Sales-and-Consumption-Status-and-Prospects-Professional-Market-Research-Report/Summary

About Us: Brandessence Market Research and Consulting Pvt. ltd.

Brandessence market research publishes market research reports & business insights produced by highly qualified and experienced industry analysts. Our research reports are available in a wide range of industry verticals including aviation, food & beverage, healthcare, ICT, Construction, Chemicals and lot more. Brand Essence Market Research report will be best fit for senior executives, business development managers, marketing managers, consultants, CEOs, CIOs, COOs, and Directors, governments, agencies, organizations and Ph.D. Students. We have a delivery center in Pune, India and our sales office is in London.

Contact us at: +44-2038074155 or mail us at [emailprotected]

Blog: https://businessstatsnews.com

Blog: http://www.dailyindustrywatch.com

Blog: https://marketsize.biz

Blog:https://technologyindustrynews.com

Blog: https://marketstatsreport.com

Blog:https://tcbiznews.com/

Top Trending Reports:

https://www.marketwatch.com/press-release/cardiac-rhythm-management-device-market-2020-global-analysis-opportunity-and-forecast-to-2025-2020-09-24?tesla=y

https://www.marketwatch.com/press-release/automotive-transmission-market-size-segmented-by-product-type-top-manufacturers-by-end-user-industry-geography-trends-and-forecast-2025-2020-09-24?tesla=y

https://www.marketwatch.com/press-release/at-103-cagr-amniotic-membrane-market-size-to-surpass-usd-18003-million-by-2025-2020-09-24?tesla=y

https://www.marketwatch.com/press-release/biomarkers-market-growing-at-a-cagr-of-141-global-industry-research-on-growth-trends-and-opportunity-2020-2025-2020-09-24?tesla=y

https://www.marketwatch.com/press-release/antimony-market-2020-cagr-of-612-with-top-countries-data-latest-trends-market-size-share-industry-analysis-and-forecast-to-2025-2020-09-24?tesla=y

Read more here:
Autologous Stem Cell and Non-Stem Cell Based Therapies MARKET 2020 |INDUSTRY ANALYSIS, SIZE, SHARE, TRENDS, MARKET DEMAND, GROWTH, OPPORTUNITIES AND...

Finding The Achilles Heel of A Killer Parasite – Newswise

Newswise DALLAS Sept. 24, 2020 Two studies led by UT Southwestern researchers shed light on the biology and potential vulnerabilities of schistosomes parasitic flatworms that cause the little-known tropical disease schistosomiasis. The findings, published online today in Science, could change the course of this disease that kills up to 250,000 people a year.

About 240 million people around the world have schistosomiasis mostly children in Africa, Asia, and South America in populations that represent the poorest of the poor, says study leader James J. Collins III, Ph.D., associate professor in UTSWs department of pharmacology.

Most of those infected survive, but those who die often suffer organ failure or parasite-induced cancer. Symptoms can be serious enough to keep people from living productive lives, Collins says.

The parasite that causes this disease has a complicated life cycle that involves stages in both freshwater snails and mammals. Dwelling in mammalian hosts circulatory systems, schistosomes feed on blood and lay copious numbers of eggs, all while causing an array of symptoms including abdominal pain, diarrhea, bloody stool, or blood in the urine. Larval worms are released from snails into water, where the flatworms then may infect humans by penetrating the skin. Schistosomiasis may become a chronic disease that affects the person for years.

Only one drug, praziquantel, is available to treat this condition. However, Collins explains, it is of limited use it doesnt kill all intramammalian stages of the schistosome life cycle, and it has a variable cure rate in some endemic settings. Theres been little interest by pharmaceutical companies in developing new drugs for this disease, he adds, because there is no monetary incentive to do so. Consequently, relatively few studies have been devoted to understanding schistosomes basic biology, which might reveal inherent weaknesses that could serve as targets for new drugs.

To that end, Collins and his colleagues embarked upon two separate studies one at the cellular level and another at the molecular level to better understand these organisms.

In the first study, the researchers delved into the cell types that make up these flatworms. Although the worms are multicellular organisms composed of a variety of unique tissue types, researchers knew little about the different cell populations in these parasites.

With a goal to create an atlas of cell types in Schistosoma mansoni one of the schistosome species that commonly causes schistosomiasis Collins and his team used a technique called single-cell RNA sequencing that distinguishes individual cell types based on their unique gene expression patterns. With this method, they identified 68 molecularly unique clusters of cells, including a population of stem cells that form the gut. When the researchers used a targeted approach called RNA interference (RNAi) to shut down the activation of a key gene in these cells, the resulting worms couldnt digest red blood cells a key to their growth and a pivotal part of the pathology they cause.

In the second study, the researchers used RNAi to sort out the function of about 20 percent of S. mansonis protein coding genes 2,216 in total. Previously, only a handful of genes in these organisms had been assessed.

By deactivating the genes one by one, Collins and his colleagues identified more than 250 genes crucial for survival. Using a database of pharmacological compounds, the researchers then searched for drugs that had the potential to act on proteins produced by these genes, identifying several compounds with activity on worms. The team also uncovered two protein kinases a group of proteins renowned for their ability to be targeted by drugs that are essential for muscle function. When these kinases were inhibited, the worms became paralyzed and eventually died, suggesting that drugs targeting these proteins could eventually treat people with schistosomiasis. A next step in the research will be to search for inhibitors of these proteins.

Collins notes that these strides in understanding the basic biology of schistosomes could eventually lead to new treatments to save untold lives in places where schistosomiasis is endemic.

This is a very important disease that most people have never heard of, he says. We need to invest and invigorate research on these parasites.

UTSW researchers who contributed to the first study include George Wendt, Lu Zhao, Rui Chen, and Michael L. Reese. UTSW researchers who contributed to the second study include Jipeng Wang, Carlos Paz, Irina Gradinaru, and Julie N. R. Collins.

The first study was supported by grants from the National Institutes of Health (R01 R01AI121037, R01 R01AI150715, R21 R21AI133393, and F30 1F30AI131509-01A1, the Welch Foundation (I-1948-20180324 and I-1936-20170325), the National Science Foundation (MCB1553334), the Burroughs Wellcome Fund, the Wellcome Trust (107475/Z/15/Z), and the Bill and Melinda Gates Foundation (OPP1171488).

The second study was supported by grants from the National Institutes of Health (R01AI121037), the Welch Foundation (I-1948-20180324), the Burroughs Wellcome Fund, and the Wellcome Trust (107475/Z/15/Z and 206194).

James Collins is Rita C. and William P. Clements, Jr. Scholar in Biomedical Research.

About UTSouthwestern Medical Center

UTSouthwestern, one of the premier academic medical centers in the nation, integrates pioneering biomedical research with exceptional clinical care and education. The institutions faculty has received six Nobel Prizes, and includes 23 members of the National Academy of Sciences, 16 members of the National Academy of Medicine, and 13 Howard Hughes Medical Institute Investigators. The full-time faculty of more than 2,500 is responsible for groundbreaking medical advances and is committed to translating science-driven research quickly to new clinical treatments. UTSouthwestern physicians provide care in about 80 specialties to more than 105,000 hospitalized patients, nearly 370,000 emergency room cases, and oversee approximately 3 million outpatient visits a year.

Read the original post:
Finding The Achilles Heel of A Killer Parasite - Newswise

SHE Initiative Shines Light on Gender Disparities in Oncology Workforce – Targeted Oncology

The Association of Community Cancer Centers (ACCC) National Oncology Conference each year helps community oncologists approach both unique and typical challenges with innovative strategies. This year, one of the challenges addressed that has been increasingly raised throughout the year was the topic of disparities in the medical field.

To close out the ACCC 37th (Virtual) National Oncology Conference, keynote speaker Nick Smith-Stanley, MBA, addressed the topic of diversity and inclusion for women in medicine, and specifically in the field of oncology.

Smith-Stanley, associate director of finance and administration, Livestrong Cancer Institutes, Dell Medical School, associate director of administration and strategic planning, Department of Oncology, Dell Medical School, The University of Texas at Austin, explained the challenges faced by women in the oncology workplace and quantified the divide seen between the number of men and women in oncology and in positions of leadership in the medical field.

By discussing the lack of women in the field of oncology, he said, it will hopefully lead to developing strategies that address such challenges, which can then lead to real change.

He also presented how the Livestrong Cancer Institutes Dell Medical School has created a program that seeks to address this gap and give the future generation of women in medicine the tools they need to succeed.

The Growing Gender Divide Across a Medical Career Span

Oncology is known to be a male-dominated field in the healthcare space. Although the number of female students and physicians in the field has grown over the past few years, the proportion of women compared to men in medicine is still less than half. Further, the numbers get lower throughout the continuum of a medical career from medical student to physician to professor and then dean.

Smith-Stanley said that, encouragingly, for the first time in history, the number of female medical students is higher than the number of male students, but the difference is marginal. The rates decrease, however, over the course of a medical career. The number of female residents and fellows is below 50% and has not changed much in the last 10 years, and specific to oncology and hematology, the proportion of female residents and fellows is below about 45%.

Among practicing physicians, only 35% are female, and within the oncology/hematology field specifically, the rate is closer to one-third. However, this is increased from 10 years ago when the rate of female physicians was only about 28% overall and about 25% in the oncology field.

Within research in general, as of 2018, 50% of STEM (science, technology, engineering, and mathematics) positions were held by women, but specifically to science and engineering, only 28% of women hold positions in these fields.

Across all disciplines in science and oncology, we see women struggling to be considered for opportunities for promotion and leadership, Smith-Stanley said. One faculty member at Dell Medical School told us that throughout her career she has seen male colleagues with fewer accomplishments get promoted at the same time. In addition, she shared that at previous institutions, rules were not as rigid for promotion and tenure for men as they were for women, they were willing to bend the rules for men, but not for women. This shows that this is not only a personal or organizational issue, it is by far a systemic issue.

He pointed out that as a result, women hold fewer positions of leadership than men. Only 19% of department chairs were held by women in the year 2019 and only 21% of full professors are female.

This poses a greater problembecause of the lack of mentorship opportunities. If our students and junior faculty are unable to identify women in positions of leadership and mentorship to help guide their career then they are less likely to progress in their career as well, he commented.

He suggested that these rates reduce across the span of a medical career due to a lack of tools, mentorship, and support given to women in medicine.

Smith-Stanley offered some strategies to bridge the gender divide through organizational changes. Starting with culture, organizational leaders must embrace and promote an all-inclusive environment. Training on diversity and bias is one way to overcome these barriers and allow for change. Providing opportunities for professional development, including mentorship and networking, can also help to retain the women in the medical workforce.

Livestrong Cancer Institutes, he said, is one of the few cancer centers across the country that is led by a woman, S. Gail Eckhardt, MD, who is the director and associate dean of cancer programs at the company. As such, Dell Medical School is focused on addressing such healthcare disparities and leaders at the Livestrong Cancer Institutes feel that they have a responsibility to address the role that women play in cancer, research, and academics.

SHE Takes a Step Towards Overcoming Gender Disparities

The Livestrong Cancer Institute stressed the use of early education and mentorship to bridge the gender gap, which ultimately led to the development of the Summer Healthcare Experience (SHE) program in oncology. SHE is a free, immersive week-long program for introducing female-identifying high school juniors and seniors to a range of career opportunities in the cancer field. The program was launched in the summer of 2019 when 8 young women from Austin were selected with health program teachers and brought to the Dell Medical School to learn more about the various careers involved with cancer care.

The SHE program sought to empower young women to take control of their education and future careers by giving them tools to overcome challenges in the workplace. The high school students were given the opportunity to participate in research and interact with the clinical teams. Participating students also came away with a general knowledge of cancer, how it is treated, and the challenges that patients with cancer and their caregivers face. Additionally, the program promoted leadership skills and professionalism that could be used throughout their career, no matter the field.

During the week, the students worked with women in the cancer center to learn about cancer anatomy and how physicians work together for the care of patients with cancer. In the wet research lab, the students were able to see cell cultures and tumor slides and they also investigated different brain tumors in the neuro-oncology lab. The students were also able to join in on the molecular tumor boards to see the interaction between various departments for deciding on optimal care for a patient. In a survivorship session, the students were also able to meet with cancer survivors and their families and learn about their cancer journeys. Additionally, the students learned about health services research in the community and how health services researchers are investigating healthcare disparities in patients with cancer.

Throughout the week, the students were able to interact with female leaders from the cancer center, including center director Eckhardt, to hear about and learn from their experiences and the challenges they faced in their careers. They also met with a number of community organizations, from American Cancer Society to the Austin Center for Grief and Loss, to hear about how these organizations are assisting patients with cancer in the city.

Its not enough to just talk about equity and inclusion. You need to have people who are invested in the conversation and the desire to make a difference. Thats exactly what we saw in the first year of SHE, Smith-Stanley said.

The students were tasked with coming up with a comprehensive care plan for a cancer case based on all they learned during the week. These plans were then presented at the end of the week to faculty from Livestrong Cancer Institutes, Dell Medical Center, the students high school teachers, and their families.

We could not have been more thrilled with the results. They were confident, they were thoughtful, they were knowledgeable, they were compassionate. The transformation that we witnessed from Monday to Friday was remarkable, Smith-Stanley commented.

Moving forward, the Livestrong Cancer Institutes hopes to expand the SHE program to more students and extend the program to 2 weeks. The program also hopes to add in more biomedical research, entrepreneurship education, a college prep day, and even a post-program internship. Livestrong Cancer Institutes is also partnering with other organizations to spread the SHE program to 4 other cancer centers, and hopefully nationwide, although this expansion has been delayed by the coronavirus disease 2019.

Reference

Smith-Stanley N. Addressing the Disparities of Women in Oncology. Presented at: ACCC National Oncology Conference; September 14-18, 2020; Virtual.

Read more:
SHE Initiative Shines Light on Gender Disparities in Oncology Workforce - Targeted Oncology

Actinium Pharmaceuticals Successfully Completes First Dosing Cohort in the Phase 1 Study of Actimab-A and Venetoclax Combination Therapy in…

NEW YORK, Sept. 23, 2020 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (the "Company" or "Actinium") today announced that it has successfully completed the first dosing cohort in the Actimab-A and venetoclax combination, multi-center Phase 1 trial for patients with Relapsed or Refractory ("R/R") Acute Myeloid Leukemia (AML) age 18 and above. All patients from the first dosing cohort (0.50 uCi/kg of Actimab-A) completed treatment and cleared their initial safety evaluation, thus allowing the study to proceed to the second dose cohort of 1.0 uCi/kg Actimab-A added to venetoclax. In a poster presentation at the American Association of Cancer Research (AACR) Annual Meeting 2019, Actimab-A was shown to be synergistic with venetoclax in venetoclax resistant cell lines, by depleting MCL-1, a protein shown to mediate resistance to venetoclax. The ongoing Phase 1 study was planned to replicate this synergy in a clinical setting. Actinium plans to report study proof of concept results in 2021.

Venetoclax is a B-Cell Lymphoma 2 (BCL-2) inhibitor jointly developed and marketed by AbbVie and Genentech that is approved in combination with hypomethylating agents ("HMAs") for patients with AML. The use of venetoclax has become widespread in the treatment of fit and unfit patients with R/R AML following its inclusion in the recently expanded National Comprehensive Cancer Network ("NCCN") guidelines. Actinium's preclinical research has demonstrated that by adding Actimab-A to venetoclax, the targeted internalized radiation from Actimab-A can deliver potent AML cell killing, as well as effectively deplete MCL-1 levels. The overexpression of MCL-1, a member of the BCL-2 family which venetoclax does not inhibit, promotes resistance to venetoclax. Thus, Actimab-A reverses resistance to venetoclax and has independent anti-leukemic activity mediated by CD33 as well.

"We are pleased to confirm that the second combination trial in our CD33 program is advancing through the dose escalation study as planned. Despite approval in multiple blood cancers, including AML, most AML patients are not cured with venetoclax regimens and eventually relapse. Based on the preclinical data, synergy with venetoclax and Actimab-A should lead to higher remission rates in R/R AML," said Dr. Mark Berger, Actinium's Chief Medical Officer. "We continue to generate promising data from our broader combination program. For example, the Actimab-A combination trial with chemotherapy agent CLAG-M increased the complete response rate compared to CLAG-M alone in R/R AML patients by 60%. We expect to complete the proof of concept Actimab-A venetoclax combination trial in 2021."

This Phase 1 study is a multicenter, open label trial of Actimab-A added to venetoclax for patients with CD33 positive R/R AML. The study will continue to enroll patients that have been previously treated with venetoclax as well as venetoclax nave patients. Gary Schiller, MD, Professor, Hematology-Oncology and Director, Hematologic Malignancy/Stem Cell Transplant Program at the UCLA Medical Center is the Principal Investigator for this study. The trial is also active at the University of Louisville.

Sandesh Seth, Actinium's Chairman and Chief Executive Officer, said, "We continue to advance the CD33 program for fit and unfit R/R AML patients as there is still a significant unmet need despite multiple recently approved agents. These therapeutic agents are not curative and patients continue to experience low response rates and/or high relapse rates. Our CD33 program, which also includes the Actimab-A CLAG-M combination trial, is anchored in leveraging mechanistic synergies of Actimab-A with approved or novel therapeutic agents in order to improve patient outcomes. We look forward to multiple clinical trial updates by year-end from our three ongoing trials in R/R AML, including our Iomab-B SIERRA Phase 3 pivotal trial."

Rationale for Actimab-A Venetoclax Combination Trial

This Phase 1/2 trial is a multicenter, open label trial of Actimab-A (lintuzumab-Ac225) added to venetoclax for patients with CD33 positive relapsed/refractory (R/R) Acute Myeloid Leukemia. The Phase 1 portion of the study is designed to determine the maximum tolerated dose (MTD) of Actimab-A added to venetoclax for R/R AML. The Phase 2 portion of the trial will assess the percentage of patients with CR, CRh, or Overall Response (CR + CRh), up to six months after the start of the treatment without receiving other AML therapies. The trial will enroll R/R AML patients who have been treated with venetoclax as well as venetoclax-nave patients. At the 1.0 uCi/kg dose, Actimab-A is administered on Day 1 of each cycle for four cycles and venetoclax is taken on Days 1-21 of each cycle for up to 4 cycles. Each cycle is 28 days, with a potential to expand to 42 days to allow for full hematologic recovery. Gary Schiller, MD, Professor, Hematology-Oncology and Director, Hematologic Malignancy/Stem Cell Transplant Program at the UCLA Medical Center is the Principal Investigator for this study.

More information on the clinical trial design is available at clinicaltrials.gov (NCT03867682).

About Actinium's CD33 Program (Actimab-A)

Antibody Radiation Conjugate (ARC) Actimab-A targets the CD33 antigen that is expressed on virtually all AML cells with the antibody lintuzumab which delivers potent alpha radiation via its Actinium-225 radioisotope payload. Blood cancers like AML are highly sensitive to radiation but cannot treated with the current standard of external beam delivery because the disease is too widespread throughout the body. The combination of targeted radiation with Actimab-A potentially allows for greater cancer cell death than a standalone chemotherapy regimen such as CLAG-M or venetoclax, which are frequently used in the treatment of fit and unfit patients with relapsed or refractory AML per National Comprehensive Cancer Network (NCCN) guidelines. Prior clinical results in over 100 patients treated with Actimab-A, including a Phase 1/2 trial of 58 patients, demonstrated a safety profile with minimal non-hematologic toxicities and an unmatched ability to deliver attenuated doses of radiation internally to CD33 expressing cancer cells. In the Phase 1/2 trial, Actimab-A as a single agent produced a 69% remission rate (CR, CRi, CRp) at high doses in patients with newly diagnosed AML but Actinium elected to pursue low dose combination trials for therapeutic development based on observed myelosuppression. In the Actimab-A CLAG-M Phase 1 combination trial, the second cohort with CLAG-M plus the 0.50 uCi/kg dose showed that 86% (6/7) of patients achieved complete remission (CR/CRi) after receiving the 0.50 uCi/kg dose of Actimab-A. This is a nearly 60% increase over the remission rate reported in a trial of seventy-four patients with relapsed or refractory AML who received CLAG-M alone. The company expects trial results, including the third dose cohort, in 2020. The Actimab-A Venetoclax Phase 1 trial continues to enroll patients in a maximum tolerated dose and expects to announce proof-of-concept results in 2021.

About Actinium Pharmaceuticals, Inc. (NYSE: ATNM)

Actinium Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing ARCs or Antibody Radiation-Conjugates, which combine the targeting ability of antibodies with the cell killing ability of radiation. Actinium's lead application for our ARCs is targeted conditioning, which is intended to selectively deplete a patient's disease or cancer cells and certain immune cells prior to a BMT or Bone Marrow Transplant, Gene Therapy or Adoptive Cell Therapy (ACT) such as CAR-T to enable engraftment of these transplanted cells with minimal toxicities. With our ARC approach, we seek to improve patient outcomes and access to these potentially curative treatments by eliminating or reducing the non-targeted chemotherapy that is used for conditioning in standard practice currently. Our lead product candidate, I-131 apamistamab (Iomab-B) is being studied in the ongoing pivotal Phase 3 Study of Iomab-B in Elderly Relapsed or Refractory Acute Myeloid Leukemia (SIERRA) trial for BMT conditioning. The SIERRA trial is over fifty percent enrolled and positive single-agent, feasibility and safety data has been highlighted at ASH, TCT, ASCO and SOHO annual meetings. I-131 apamistamab will also be studied as a targeted conditioning agent in a Phase 1/2 anti-HIV stem cell gene therapy with UC Davis and is expected to be studied with a CAR-T therapy in 2020. In addition, we are developing a multi-disease, multi-target pipeline of clinical-stage ARCs targeting the antigens CD45 and CD33 for targeted conditioning and as a therapeutic either in combination with other therapeutic modalities or as a single agent for patients with a broad range of hematologic malignancies including acute myeloid leukemia, myelodysplastic syndrome and multiple myeloma. Ongoing combination trials include our CD33 alpha ARC, Actimab-A, in combination with the salvage chemotherapy CLAG-M and the Bcl-2 targeted therapy venetoclax. Underpinning our clinical programs is our proprietary AWE (Antibody Warhead Enabling) technology platform. This is where our intellectual property portfolio of over 100 patents, know-how, collective research and expertise in the field are being leveraged to construct and study novel ARCs and ARC combinations to bolster our pipeline for strategic purposes. Our AWE technology platform is currently being utilized in a collaborative research partnership with Astellas Pharma, Inc. Website: https://www.actiniumpharma.com/

Forward-Looking Statements for Actinium Pharmaceuticals, Inc.

This press release may contain projections or other "forward-looking statements" within the meaning of the "safe-harbor" provisions of the private securities litigation reform act of 1995 regarding future events or the future financial performance of the Company which the Company undertakes no obligation to update. These statements are based on management's current expectations and are subject to risks and uncertainties that may cause actual results to differ materially from the anticipated or estimated future results, including the risks and uncertainties associated with preliminary study results varying from final results, estimates of potential markets for drugs under development, clinical trials, actions by the FDA and other governmental agencies, regulatory clearances, responses to regulatory matters, the market demand for and acceptance of Actinium's products and services, performance of clinical research organizations and other risks detailed from time to time in Actinium's filings with the Securities and Exchange Commission (the "SEC"), including without limitation its most recent annual report on form 10-K, subsequent quarterly reports on Forms 10-Q and Forms 8-K, each as amended and supplemented from time to time.

Contacts:

Investors: Clayton Robertson Actinium Pharmaceuticals, Inc. crobertson@actiniumpharma.com

Hans Vitzthum LifeSci Advisors, LLC Hans@LifeSciAdvisors.com (617) 535-7743

View original content to download multimedia:http://www.prnewswire.com/news-releases/actinium-pharmaceuticals-successfully-completes-first-dosing-cohort-in-the-phase-1-study-of-actimab-a-and-venetoclax-combination-therapy-in-relapsedrefractory-aml-patients-301136354.html

SOURCE Actinium Pharmaceuticals, Inc.

Company Codes: AMEX:ATNM

See more here:
Actinium Pharmaceuticals Successfully Completes First Dosing Cohort in the Phase 1 Study of Actimab-A and Venetoclax Combination Therapy in...